The fbpA/sapM Double Knock Out Strain of Mycobacterium tuberculosis Is Highly Attenuated and Immunogenic in Macrophages

HIV and Tuberculosis: a Deadly Human Syndemic

(2011) C. K. Kwan et al.   CLINICAL MICROBIOLOGY REVIEWS

Disruption of the SapM locus inMycobacterium bovisBCG improves its protective efficacy as a vaccine againstM. tuberculosis

(2011) Nele Festjens et al.   EMBO Molecular Medicine

Lysine Auxotrophy Combined with Deletion of the SecA2 Gene Results in a Safe and Highly Immunogenic Candidate Live Attenuated Vaccine for Tuberculosis

(2011) Joseph Hinchey et al.   PLoS One

Novel tuberculosis vaccines on the horizon

(2010) Shreemanta K Parida et al.   CURRENT OPINION IN IMMUNOLOGY

Immunogenicity and Protection Induced by a Mycobacterium tuberculosis sigE Mutant in a BALB/c Mouse Model of Progressive Pulmonary Tuberculosis

(2010) R. H. Pando et al.   INFECTION AND IMMUNITY

Interactions of Attenuated Mycobacterium tuberculosis phoP Mutant with Human Macrophages

(2010) Nadia L. Ferrer et al.   PLoS One

Cell-Mediated Immune Responses in Tuberculosis

(2009) Andrea M. Cooper   Annual Review of Immunology

Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells

(2009) Chinnaswamy Jagannath et al.   NATURE MEDICINE

Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates

(2009) Michelle H. Larsen et al.   VACCINE

The ΔfbpA mutant derived from Mycobacterium tuberculosis H37Rv has an enhanced susceptibility to intracellular antimicrobial oxidative mechanisms, undergoes limited phagosome maturation and activates macrophages and dendritic cells

(2008) Muralidhar K. Katti et al.   CELLULAR MICROBIOLOGY

Live tuberculosis vaccines based onphoPmutants: a step towards clinical trials

(2008) Jesus A Gonzalo Asensio et al.   EXPERT OPINION ON BIOLOGICAL THERAPY